Pfizer Ltd.'s consolidated net profit rose 27% during the first quarter of the current financial year.
The drugmaker's bottom line soared to Rs 191.75 crore during the April-June period, compared to Rs 150.71 crore during the same period last year, according to an exchange filing on Wednesday.
Pfizer Q1 FY26 Highlights (Consolidated, YoY)
Revenue up 7.1% to Rs 603.05 crore versus Rs 562.86 crore.
Net profit up 27% to Rs 191.75 crore versus Rs 150.71 crore.
Ebitda up 18% to Rs 210.02 crore versus Rs 177.49 crore.
Margin at 34.8% versus 31.5%.
Pfizer on Wednesday proposed to launch its 20-valent pneumococcal conjugate vaccine for adults in India, helping against pneumococcal disease in adults, the press release said.
The vaccine helps against 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease. It helps in proactive protection for all adults along with those living with chronic conditions.
Shares of Pfizer closed 0.1% higher at Rs 5,107 apiece on the NSE, compared to a 0.54% rise in the benchmark Nifty. The stock has fallen 11.76% in the last 12 months and 1.09% on a year-to-date basis.
Out of the four analysts tracking the company, two have a 'buy' rating on the stock, one suggests 'sell' and another recommends 'hold', according to Bloomberg data. The average of 12-month analysts' price targets implies a potential upside of 22.3%.
RECOMMENDED FOR YOU
Pfizer Launches Next-Gen Vaccine For Pneumococcal Disease
Aug 11, 2025
Closed For Business: In Times Of Heightened Uncertainty, RBI Has Discontinued Nowcasts
Aug 02, 2025
RBI Lifts Restrictions On Religare Finvest After Seven Years Under Corrective Action Plan
Jul 23, 2025
'Buy' PN Gadgil Shares Reiterates Motilal Oswal — Here's Why
Jul 09, 2025
POPULAR